Viatris Inc.

American global pharmaceutical company formed in 2020 through the merger of Upjohn and Mylan, known for generic and brand-name medicines, headquartered in Canonsburg, Pennsylvania.

Viatris was formed in 2020 through the merger of Upjohn and Mylan. Upjohn was a legacy business of Pfizer focused on established medicines including Lipitor, Viagra, and other brand-name products. Mylan was a global generic pharmaceutical company with a strong presence in generic medicines and biosimilars. The merger created a new company focused on providing access to affordable medicines.

The merger was announced in 2019 and completed in November 2020. The combined company was named Viatris, derived from the Latin words "via" meaning path and "tris" meaning three, representing the company's three pillars of access, innovation, and reliability. The merger brought together Upjohn's portfolio of established brand-name medicines and Mylan's generic pharmaceutical capabilities.

Following the merger, Viatris focused on integrating the two companies and optimizing its portfolio. The company divested non-core assets and focused on its core therapeutic areas including cardiovascular, respiratory, and central nervous system. Viatris also invested in manufacturing capabilities and supply chain to support its global operations.

Recent strategic direction has focused on expanding access to affordable medicines and optimizing the product portfolio. Viatris has invested in biosimilars and complex generics to expand its portfolio. The company has also focused on emerging markets to drive growth. Viatris continues to integrate its operations and optimize its cost structure.